Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Tri-VyLibra

×

Overview

What is Tri-VyLibra?

Tri-VyLibra is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).

Each active white tablet contains 0.180 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.

Each active light blue tablet contains 0.215 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.

Each active dark blue tablet contains 0.250 mg of norgestimate USP and 0.035 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide.

Each green tablet contains only inert ingredients, as follows: anhydrous lactose, FD&C Blue No. 2 aluminum lake, ferric oxide yellow, magnesium stearate, microcrystalline cellulose, and povidone.



What does Tri-VyLibra look like?



What are the available doses of Tri-VyLibra?

Tri-VyLibra consists of 28 round, biconvex tablets in the following order ():

What should I talk to my health care provider before I take Tri-VyLibra?

Nursing mothers: Not recommended; can decrease milk production. ()

How should I use Tri-VyLibra?

Tri-VyLibra tablets are indicated for use by females of reproductive potential to prevent pregnancy .

Tri-VyLibra is  available in blister pack . Tri-VyLibra may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first  7 consecutive days of administration.


What interacts with Tri-VyLibra?

Sorry No Records found


What are the warnings of Tri-VyLibra?

Sorry No Records found


What are the precautions of Tri-VyLibra?

Sorry No Records found


What are the side effects of Tri-VyLibra?

Sorry No records found


What should I look out for while using Tri-VyLibra?

Do not prescribe Tri-VyLibra to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke


What might happen if I take too much Tri-VyLibra?

There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Tri-VyLibra?

StorageStore CLENPIQ at 25°C (77°F). Excursions permitted at 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Do not refrigerate or freeze.StorageStore CLENPIQ at 25°C (77°F). Excursions permitted at 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Do not refrigerate or freeze.Product: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLEProduct: 71335-0309NDC: 71335-0309-5 18 TABLET in a BOTTLENDC: 71335-0309-3 90 TABLET in a BOTTLENDC: 71335-0309-1 30 TABLET in a BOTTLENDC: 71335-0309-4 28 TABLET in a BOTTLENDC: 71335-0309-2 60 TABLET in a BOTTLEProduct: 71335-0349NDC: 71335-0349-2 30 TABLET in a BOTTLENDC: 71335-0349-3 60 TABLET in a BOTTLENDC: 71335-0349-4 90 TABLET in a BOTTLENDC: 71335-0349-1 100 TABLET in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of ethinyl estradiol and norgestimate increases sex hormone-binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established.

Non-Clinical Toxicology
Do not prescribe Tri-VyLibra to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke

HMG-CoA reductase inhibitors:

Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. Limit the dose of simvastatin in patients on verapamil to 10 mg daily. Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.

Ivabradine:

Beta-blockers:

Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.

A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. A variable effect has been seen when verapamil and atenolol were given together.

Digitalis

Antihypertensive agents

Antiarrhythmic agents:













The electrophysiologic effects of quinidine and verapamil on AV conduction were studied in 8 patients. Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy.

Other agents:

























































T

h

r

o

m

b

oe

m

b

ol

ic Disorders and Other Vascular Problems:

L

i

ver

d

isease:

H

igh blood pressure:

Carbohydrate and lipid metabolic effects:

Headache:

Bleeding Irregularities and Amenorrhea:

The  following serious  adverse  reactions  with  the  use  of  COCs  are  discussed  elsewhere  in labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).